Companies › Innolake Biopharm
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ILB-3101 B7-H3-targeting antibody-drug conjugate | CD276 | Phase 1 | Advanced Solid Tumor | – |
| ILB2109 A2a receptor antagonist | ADORA2A | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05278546 | ILB2109 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2024 |
| NCT06426680 | ILB-3101 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2025 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.